Table 2 Patients’ microbiological presentation, bacterial species, and antibiotic susceptibility test
Total (n = 156) | Carbapenem therapy (n = 69) | Non-carbapenem therapy (n = 87) | p-value | |
|---|---|---|---|---|
Microbiological presentation | ||||
Blood cultures performed | 145 (93) | 63 (91) | 82 (94) | 0.69 |
Concomitant bloodstream infection | 109 (75) | 52 (82) | 57 (69) | 0.07 |
Coinfection | 6 (4) | 3 (4) | 3 (3) | 1 |
ESBL fecal carriage | 50 (32) | 21 (30) | 29 (33) | 0.31 |
Bacterial species | ||||
Escherichia coli | 79 (51) | 33 (48) | 46 (53) | 0.73 |
Klebsiella pneumoniae | 46 (29) | 22 (32) | 24 (27) | |
Enterobacter cloacae | 15 (10) | 8 (12) | 7 (8) | |
Klebsiella oxytoca, | 4 (2) | 2 (3) | 2 (2) | |
Proteus mirabilis | 4 (2) | 2 (3) | 2 (2) | |
Citrobacter koseri | 3 (2) | 2 (3) | 1 (1) | |
Citrobacter freundii | 3 (2) | 0 (0) | 3 (3) | |
Morganella morganii | 2 (1) | 0 (0) | 2 (2) | |
Antibiotic susceptibility test | ||||
Susceptibility to piperacillin–tazobactam | 90 (60) | 33 (48) | 57 (65) | 0.06 |
Susceptibility to aminoglycoside | 142 (91) | 62 (90) | 80 (92) | 0.91 |
Susceptibility to piperacillin–tazobactam and/or aminoglycoside | 148 (95) | 65 (94) | 83 (95) | 1 |
Susceptibility to cefoxitin | 91 (58) | 37 (54) | 54 (62) | 0.06 |
Susceptibility to ertapenem, n (%) | 148 (95) | 64 (93) | 84 (96) | 0.45 |
Susceptibility to fluoroquinolone, n (%) | 20 (13) | 7 (10) | 13 (15) | 0.47 |
Susceptibility to cotrimoxazole/trimethoprim, n (%) | 46 (29) | 23 (33) | 23 (26) | 0.38 |